JHDD start-up Lorem Therapeutics gets funding from IP Group
JHDD start-up Dracen Pharmaceuticals receives $40.5 million to develop Glutamine Antagonists
JHDD receives 5th TEDCO Maryland Innovation Initiative Award
-MS882, an inhibitor of neutral sphingomyelinase-2, for the treatment of Alzheimer’s Disease
Our high throughput screening collaboration with Eisai and partnership with Institute of Organic Chemistry and Biochemistry represent innovative ways to create a great synergy of complimentary organizations working together to develop new therapeutics.